Comparison of the prevalence of all diagnosed diseases among Estonian Biobank participants against the general population

Read full text
Authors: Maarja Pajusalu, Marek Oja, Kerli Mooses, Silver Heinsar, Oliver Aasmets, Triin Laisk, Palta Priit, Org Elin, Reedik Mägi, Urmo Võsa, Krista Fischer, Taavi Tillmann
+4 more Sven Laur, Sulev Reisberg, Jaak Vilo, Raivo Kolde
Cited by: 0
References: 23

Abstract

Abstract Characterizing study sample representativeness is critical for the validity of biobank-derived findings, yet selection biases are rarely quantified across the full clinical spectrum. Here we systematically evaluate the Estonian Biobank (EstBB) - comprising ∼20% of the adult population - by comparing two recruitment waves against a 30% national reference dataset (Est-Health-30). Analyzing prevalence ratios (PR) across 1,028 ICD-10 categories, we reveal a bifurcated landscape of representativeness. While EstBB achieves population parity (PR ∼ 1.0) for widespread chronic conditions like Type 2 diabetes, 47% of diagnostic categories exhibit significant deviations (>1.3-fold). We identify a distinct “managed symptomatic” phenotype: a systematic enrichment of outpatient diagnoses - such as melanocytic nevi (PR=2.07, 95% CI 1.93…2.21) and major depression (PR=1.53, 1.4…1.66) - coupled with a depletion of high-mortality conditions like lung cancer (PR=0.69, 0.64…0.75) and vascular dementia (PR=0.45, 0.38…0.54). These biases evolved across recruitment phases, with the later EstBB2 cohort exhibiting a healthier, prevention-oriented profile. To support research integrity, we provide an interactive open-access dashboard for phenotype refinement. Accounting for such selection-driven “clinical visibility” is essential to avoid collider bias in risk prediction and causal inference models.

Fields of Study & Subjects

Health Environment Cognitive Aging Statistical Methods in Epidemiology Ethics in Clinical Research

Publication details

Journal / source
medRxiv
Publication date
6 February 2026
Document type
Preprint